Total Payments
$132,719
2024 Payments
$9,997
Companies
85
Transactions
1,188
Medicare Patients
5,524
Medicare Billing
$1.2M
Payment Breakdown by Category
Consulting$64,598 (48.7%)
Other$32,832 (24.7%)
Food & Beverage$19,480 (14.7%)
Travel$13,682 (10.3%)
Education$2,126 (1.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $64,598 | 37 | 48.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $26,623 | 12 | 20.1% |
| Food and Beverage | $19,480 | 1,034 | 14.7% |
| Travel and Lodging | $13,682 | 43 | 10.3% |
| Honoraria | $6,210 | 7 | 4.7% |
| Education | $2,126 | 55 | 1.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $17,003 | 70 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $15,398 | 75 | $0 (2024) |
| Celgene Corporation | $12,130 | 39 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $9,733 | 53 | $0 (2024) |
| SOBI, INC | $8,999 | 14 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $6,895 | 32 | $0 (2024) |
| GENZYME CORPORATION | $6,674 | 19 | $0 (2024) |
| Dova Pharmaceuticals | $5,963 | 5 | $0 (2020) |
| Exelixis Inc. | $5,834 | 23 | $0 (2023) |
| Pharmacosmos Therapeutics Inc. | $5,484 | 4 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $9,997 | 135 | AstraZeneca Pharmaceuticals LP ($3,885) |
| 2023 | $8,665 | 166 | AstraZeneca Pharmaceuticals LP ($3,820) |
| 2022 | $22,946 | 158 | Sobi, Inc ($8,799) |
| 2021 | $13,998 | 130 | Pharmacosmos Therapeutics Inc. ($2,300) |
| 2020 | $8,251 | 98 | Pharmacosmos Therapeutics Inc. ($3,150) |
| 2019 | $23,092 | 147 | Bayer HealthCare Pharmaceuticals Inc. ($6,562) |
| 2018 | $25,287 | 173 | Celgene Corporation ($7,381) |
| 2017 | $20,482 | 181 | Genentech USA, Inc. ($15,918) |
All Payment Transactions
1,188 individual payment records from CMS Open Payments — Page 1 of 48
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | SEAGEN INC. | — | Education | In-kind items and services | $98.65 | General |
| 12/12/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $19.51 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $18.04 | General |
| Category: ONCOLOGY | ||||||
| 12/11/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $29.68 | General |
| Category: Oncology | ||||||
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $20.63 | General |
| Category: Oncology | ||||||
| 12/05/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $23.43 | General |
| Category: ONCOLOGY | ||||||
| 12/03/2024 | AstraZeneca Pharmaceuticals LP | Truqap (Drug) | Consulting Fee | Cash or cash equivalent | $1,665.00 | General |
| Category: Oncology | ||||||
| 12/03/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $21.61 | General |
| Category: ONCOLOGY | ||||||
| 11/26/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $26.30 | General |
| Category: ONCOLOGY | ||||||
| 11/26/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $22.20 | General |
| Category: Hematology/Oncology | ||||||
| 11/21/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $14.27 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $23.13 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $21.31 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $13.15 | General |
| 10/31/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $15.99 | General |
| Category: Oncology | ||||||
| 10/30/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $31.14 | General |
| Category: Oncology | ||||||
| 10/29/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $14.80 | General |
| Category: ONCOLOGY | ||||||
| 10/28/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $14.97 | General |
| Category: HORMONE THERAPY | ||||||
| 10/24/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $20.75 | General |
| Category: Oncology | ||||||
| 10/22/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $19.28 | General |
| Category: ONCOLOGY | ||||||
| 10/18/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $24.06 | General |
| Category: Oncology | ||||||
| 10/17/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $26.86 | General |
| 10/17/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Education | In-kind items and services | $16.30 | General |
| Category: Oncology | ||||||
| 10/15/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $26.86 | General |
| Category: ONCOLOGY | ||||||
| 10/14/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $22.46 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 1,407 | 3,468 | $696,055 | $319,406 |
| 2022 | 10 | 1,343 | 3,570 | $704,445 | $320,935 |
| 2021 | 9 | 1,261 | 3,328 | $652,940 | $311,699 |
| 2020 | 11 | 1,513 | 3,511 | $689,824 | $279,882 |
Total Patients
5,524
Total Services
13,877
Medicare Billing
$1.2M
Procedure Codes
51
All Medicare Procedures & Services
51 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 190 | 956 | $191,100 | $104,087 | 54.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 369 | 683 | $119,525 | $65,482 | 54.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 207 | 599 | $104,825 | $44,586 | 42.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 146 | 638 | $127,600 | $40,290 | 31.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 113 | 140 | $28,000 | $18,847 | 67.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 109 | 130 | $45,500 | $13,445 | 29.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 54 | 96 | $21,600 | $9,120 | 42.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 51 | 53 | $17,225 | $7,337 | 42.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 38 | 38 | $12,350 | $6,451 | 52.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 44 | 44 | $11,880 | $4,865 | 41.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 16 | 16 | $5,200 | $2,311 | 44.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 29 | 31 | $4,650 | $1,470 | 31.6% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 24 | 26 | $3,900 | $667.16 | 17.1% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 17 | 18 | $2,700 | $446.94 | 16.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 165 | 694 | $138,800 | $77,647 | 55.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 209 | 947 | $165,725 | $72,922 | 44.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 381 | 708 | $123,900 | $66,755 | 53.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 125 | 628 | $125,600 | $35,998 | 28.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 105 | 152 | $30,400 | $21,086 | 69.4% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 113 | 137 | $47,950 | $14,938 | 31.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 42 | 84 | $18,900 | $6,941 | 36.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 51 | 51 | $13,770 | $6,648 | 48.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 40 | 40 | $13,000 | $6,489 | 49.9% |
| 99358 | Extended patient service without direct patient contact, first hour | Facility | 2022 | 41 | 50 | $10,000 | $4,475 | 44.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 23 | 26 | $8,450 | $4,162 | 49.2% |
About Dr. Qamar Zaman, MD
Dr. Qamar Zaman, MD is a Hematology & Oncology healthcare provider based in Cumberland, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1093893331.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Qamar Zaman, MD has received a total of $132,719 in payments from pharmaceutical and medical device companies, with $9,997 received in 2024. These payments were reported across 1,188 transactions from 85 companies. The most common payment nature is "Consulting Fee" ($64,598).
As a Medicare-enrolled provider, Zaman has provided services to 5,524 Medicare beneficiaries, totaling 13,877 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 51 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Cumberland, MD
- Active Since 11/02/2006
- Last Updated 02/01/2012
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1093893331
Products in Payments
- Avastin (Biological) $11,407
- OPDIVO (Biological) $9,557
- DOPTELET (Drug) $8,799
- JEVTANA (Drug) $6,459
- Doptelet (Drug) $5,963
- Cabometyx (Drug) $5,799
- Nexavar (Drug) $5,566
- Monoferric (Drug) $5,450
- IMFINZI (Biological) $5,169
- Trodelvy (Drug) $4,387
- TECENTRIQ (Biological) $4,317
- TAGRISSO (Drug) $3,087
- LYNPARZA (Drug) $2,742
- Inrebic (Drug) $2,661
- CALQUENCE (Drug) $2,373
- Nplate (Biological) $2,034
- BLENREP (Biological) $2,018
- KRAZATI (Drug) $1,964
- Lonsurf (Drug) $1,699
- Truqap (Drug) $1,665
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.